Brazikumab ( AMG139, formerly known as MEDI2070 ) is a significant therapeutic agent targeting IL-17F . Recent trial results from the phase 3 IMMU-NYMPH3 investigation evaluating its effectiveness in patients with severe psoriaatic arthritis have indicated mixed findings. While preliminary data suggested substantial benefits in arthritis severity ,